Last $1.16 USD
Change Today 0.00 / 0.00%
Volume 630.8K
VICL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

10390 Pacific Center Court

San Diego, CA 92121

United States

Phone: 858-646-1100

Fax: 858-646-1150

Vical Incorporated is engaged in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company has three active, independent or partnered, development programs in the area of infectious disease consists of an ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus (CMV), reactivation in stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc.; an ongoing Phase 1/2 clinical trial using its Vaxfectin-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of recurrent genital herpes; and a completed preclinical program, with an allowed investigational new drug application, using its CyMVectin prophylactic vaccine formulated with its proprietary Vaxfectin adjuvant to prevent CMV infection before and during pregnancy. The company develops ASP0113 therapeutic vaccine for CMV that is used to protect against infection after stem cell transplants, which is in Phase 3 clinical trail. It also develops ASP0113 therapeutic vaccine for CMV that is used to protect against infection after solid organ transplants, which is in Phase 2 clinical trail. The company develops tetravalent dengue vaccine that is used to prevent dengue disease caused by all 4 dengue serotypes. The Naval Medical Research Center has initiated a Phase 1 study of a tetravalent (serotypes 1, 2, 3, and 4) dengue DNA vaccine formulated with Vaxfectin. The company markets ONCEPT therapeutic cancer vaccine encoding human tyrosinase that is used to adjunct treatment to increase survival time of dogs with oral melanoma. The company has licensing arrangements with AnGes MG, Inc.; Aqua Health Ltd. of Canada, an affiliate of Novartis Animal Health; Merial Limited, a subsidiary of Sanofi; and others. The company has granted non-exclusive, academic licenses to its DNA delivery technology patent estate to 11 research institutions, including Stanford, Harvard, Yale and the Massachusetts Institute of Technology. Business Strategy The company's business strategy is to develop products independently; enhance and expand its technologies; expand the applications of its technologies through strategic collaborations; and pursue contract manufacturing opportunities. In-licensing The company has agreement with CytRx Corporation (CytRx), which grants it rights to use or sublicense CytRx’s poloxamer technology to enhance viral or non-viral delivery of polynucleotides in all unexcluded preventive and therapeutic human and animal health applications, including CMV. The company has licensed from the City of Hope on an exclusive basis various U.S. patents that provide protection for CMV-related polynucleotide based vaccines, including TransVax and CyMVectin vaccine candidates. Intellectual Property Core DNA Delivery Technology: The company and the Wisconsin Alumni Research Foundation (WARF) co-own rights to issued U.S. patents covering its core DNA delivery technology, including patents on methods of administering DNA sequences for the purposes of expressing therapeutic proteins or for inducing immune responses and the administration of DNA sequences into blood vessels and the heart. The WARF exclusively licensed its rights in the core DNA delivery technology to the company. The remaining patents in this family expire by December 30, 2014. Lipid Technologies: The company is the sole assignee of issued U.S. patents covering various cationic lipid compounds that are used to facilitate delivery of gene therapies to some tissues. Its HSV-2 therapeutic vaccine candidate, its Vaxfectin adjuvant, as well as its CyMVectin prophylactic vaccine candidate is protected in-part by lipid technology and/or lipid compound patents that extend up to March 24, 2020. Specific DNA Products: The company has supplemented the broad patent coverage described above with patents covering specific product applications of its technologies. The issued patents expire between Dece

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VICL:US $1.16 USD 0.00

VICL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $3.17 USD -0.07
Dynavax Technologies Corp $1.44 USD +0.09
Eurocine Vaccines AB kr14.75 SEK +1.65
GenVec Inc $2.07 USD -0.10
Progenics Pharmaceuticals Inc $5.08 USD -0.14
View Industry Companies
 

Industry Analysis

VICL

Industry Average

Valuation VICL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.7x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VICAL INC, please visit www.vical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.